Startseite Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies

  • Michela Cini EMAIL logo , Cristina Legnani , Mirella Frascaro , Claudia Pancani , Costanza Cappelli , Giuseppina Rodorigo , Lelia Valdrè und Benilde Cosmi
Veröffentlicht/Copyright: 10. Oktober 2015
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background:

Laboratory investigation with specific factor XIII (FXIII) assays plays a crucial role in diagnosis of FXIII deficiency. According to the International Society on Thrombosis and Hemostasis (ISTH), it is necessary a blank sample with iodoacetamide, provided by the kit or locally prepared, when the ammonia release assays are used, to avoid FXIII activity overestimation.

Methods:

In this study we set up a modification of the Berichrom FXIII chromogenic assay, in which iodoacetamide was added by the BCS analyzer in the reaction mixture of the blank sample, without modifications of the original reagents. We analyzed 100 plasma samples of outpatients with clinical symptoms suggestive of a bleeding diathesis (20 samples had FXIII activity <20%).

Results:

In all samples blank subtraction significantly reduced FXIII activity, mostly in the low activity range group (from 10.1% to 2.4%, p<0.0001). In this group correction with iodoacetamide also increased the agreement with the immunoassay and allowed FXIII activity measure up to 0%.

Conclusions:

Despite the low number of samples included in the study, the described automatic procedure seemed to decrease FXIII activity overestimation and, especially for low activity range samples (<20%), to improve the agreement between FXIII activity and concentration. Our data suggested that iodoacetamide correction could allow the detection of severe FXIII deficiencies (activity <5%) otherwise undiagnosed using the original method.


Corresponding author: Michela Cini, Department of Angiology and Blood Coagulation, University Hospital S.Orsola-Malpighi, Via Albertoni 15, 40138 Bologna, Italy, E-mail:

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013;39:632–41.10.1055/s-0033-1353392Suche in Google Scholar PubMed

2. Katona E, Penzes K, Molnar E, Muszbek L. Measurement of factor XIII activity in plasma. Clin Chem Lab Med 2012;50:1191–202.10.1515/cclm-2011-0730Suche in Google Scholar PubMed

3. Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011;9:1404–6.10.1111/j.1538-7836.2011.04315.xSuche in Google Scholar PubMed

4. Ajzner E, Muszbek L. Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency: a rebuttal. J Thromb Haemost 2004;2:2075–7.10.1111/j.1538-7836.2004.00986.xSuche in Google Scholar PubMed

5. Meijer P. Clinically needed sensitivity for very low levels of Factor XIII: not yet proven for a new functional assay. Clin Chem Lab Med 2011;49:1753–4.10.1515/CCLM.2011.649Suche in Google Scholar PubMed

6. Hsu P, Zantek ND, Meijer P, Hayward CP, Brody J, Zhang X, et al. Factor XIII assays and associated problems for laboratory diagnosis of factor XIII deficiency: an analysis of international proficiency testing results. Semin Thromb Hemost 2014;40:232–8.10.1055/s-0034-1365841Suche in Google Scholar PubMed

7. Ichinose A. Hemorrhagic acquired Factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 2011;37:382–8.10.1055/s-0031-1276587Suche in Google Scholar PubMed

8. Legnani C, Cosmi B, Cini M, Frascaro M, Guazzaloca G, Palareti G. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004;124:504–10.10.1046/j.1365-2141.2003.04795.xSuche in Google Scholar PubMed

9. Legnani C, Palareti G, Guazzaloca G, Cosmi B, Lunghi B, Bernardi F, et al. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2002;23:984–90.10.1053/euhj.2001.3082Suche in Google Scholar PubMed

10. Karpati L, Penke B, Katona E, Balogh I, Vamosi G, Muszbek L. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem 2000;46:1946–55.10.1093/clinchem/46.12.1946Suche in Google Scholar

11. Lawrie AS, Green L, Mackie IJ, Liesner R, Machin SJ, Peyvandi F. Factor XIII–an under diagnosed deficiency – are we using the right assays? J Thromb Haemost 2010;8:2478–82.10.1111/j.1538-7836.2010.04028.xSuche in Google Scholar PubMed

Received: 2015-6-11
Accepted: 2015-9-10
Published Online: 2015-10-10
Published in Print: 2016-5-1

©2016 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Protein S100B: from cancer diagnostics to the evaluation of mild traumatic brain injury
  4. Reviews
  5. Capillary electrophoresis based on nucleic acid detection for diagnosing human infectious disease
  6. Oxidative damage and the pathogenesis of menopause related disturbances and diseases
  7. Opinion Paper
  8. EFLM WG-Preanalytical phase opinion paper: local validation of blood collection tubes in clinical laboratories
  9. Genetics and Molecular Diagnostics
  10. Effective quality management practices in routine clinical next-generation sequencing
  11. Analysis of PMP22 duplication and deletion using a panel of six dinucleotide tandem repeats
  12. A novel exonuclease (TaqMan) assay for rapid haptoglobin genotyping
  13. General Clinical Chemistry and Laboratory Medicine
  14. Heparinate but not serum tubes are susceptible to hemolysis by pneumatic tube transportation
  15. Criteria of adequacy for vitamin D testing and prevalence of deficiency in clinical practice
  16. A simple clot based assay for detection of procoagulant cell-derived microparticles
  17. Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies
  18. Immunoassay or LC-MS/MS for the measurement of salivary cortisol in children?
  19. Head to head evaluation of the analytical performance of two commercial methotrexate immunoassays and comparison with liquid chromatography-mass spectrometry and the former fluorescence polarization immunoassay
  20. Reference Values and Biological Variations
  21. Preanalytical, analytical, gestational and pediatric aspects of the S100B immuno-assays
  22. Establishment of reference intervals of clinical chemistry analytes for the adult population in Saudi Arabia: a study conducted as a part of the IFCC global study on reference values
  23. First data on the biological variation and quality specifications for plasma ammonia concentrations in healthy subjects
  24. Cancer Diagnostics
  25. Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome
  26. Cardiovascular Diseases
  27. Galectin-3, osteopontin and successful aging
  28. Platelet volume is associated with the Framingham risk score for cardiovascular disease in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
  29. Infectious Diseases
  30. Diagnostic values of CD64, C-reactive protein and procalcitonin in ventilator-associated pneumonia in adult trauma patients: a pilot study
  31. Corrigendum
  32. Corrigendum to: Accuracy of GFR estimating equations combining standardized cystatin C and creatinine assays: a cross-sectional study in Sweden
  33. Letters to the Editor
  34. Theranos phenomenon – part 3
  35. Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice
  36. Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice
  37. Impact of specimen mixing methods on presepsin point-of-care test results using whole blood
  38. Clinical laboratories have a critical role in test strip lot management in glucose point-of-care testing
  39. Hemoglobin A2-Leuven (α2δ2 143(H21) His>Asp): a novel delta-chain variant potentially interfering in hemoglobin A1c measurement using cation exchange HPLC
  40. Eryptosis is induced by hyperthermia in hereditary spherocytosis red blood cells
  41. Investigation of sensitivity for coagulation factor deficiency in APTT and PT: how to perform it?
  42. Underestimation of hepcidin concentration by time of flight mass spectrometry and competitive ELISA in hepcidin p.Gly71Asp heterozygotes
  43. Congress Abstracts
  44. ISMD2016 Eleventh International Symposium on Molecular Diagnostics
Heruntergeladen am 16.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2015-0547/html
Button zum nach oben scrollen